Posted by Michael Wonder on 31 Mar 2022
Novavax submits request to expand conditional marketing authorisation of COVID-19 vaccine in the European Union to adolescents (ages 12-17)
31 March 2022 - If granted, Nuvaxovid COVID-19 vaccine (recombinant, adjuvanted) would be the first protein-based option for adolescents aged 12-17 years in Europe,
Novavax today announced submission of its request to expand the conditional marketing authorisation of Nuvaxovid COVID-19 vaccine (recombinant, adjuvanted) in the European Union to adolescents aged 12 through 17 years.
